Mankind Pharma has received regulatory approval from India's Central Drugs Standard Control Organisation (CDSCO) to begin Phase 1 clinical trials for MKP11093, a novel molecule designed to treat multiple autoimmune disorders. The approval marks a significant advancement in the company's efforts to develop innovative treatments for conditions with substantial unmet medical needs.
Novel JAK Inhibitor Targets Multiple Conditions
MKP11093 is being developed as a treatment for several autoimmune disorders, including rheumatoid arthritis, ulcerative colitis, plaque psoriasis, and alopecia. The molecule was developed at the Mankind Research Centre and has demonstrated strong results in preclinical studies with a promising safety and selectivity profile.
According to Arjun Juneja, Chief Operating Officer of Mankind Pharma, "The development of MKP11093 is a major milestone representing the company's endeavour to deliver a best-in-class JAK inhibitor that maximises therapeutic potential while addressing the safety concerns associated with conventional approaches."
Phase 1 Trial Design and Objectives
The upcoming Phase 1 trial is expected to begin shortly and will evaluate the safety, tolerability, and pharmacokinetics of MKP11093 in healthy volunteers. The study will employ both single and multiple-ascending dose studies to comprehensively assess the drug's profile in human subjects.
This regulatory milestone represents Mankind Pharma's commitment to advancing innovative therapeutic solutions for autoimmune disorders, an area where current treatment options often come with significant safety concerns. The company's focus on developing a JAK inhibitor with improved safety characteristics could potentially address key limitations of existing therapies in this therapeutic class.
